Author: Claude (AI), from PubMed abstracts · Reviewed by: Dr Mina Abdelmseih · Reviewed: 2026-11-15 · Review due: 2027-11-15

Educational content only. Not personalised medical advice. Clinical decisions remain the responsibility of the treating clinician.

Behçet Uveitis

Behçet's syndrome is a chronic, relapsing, multisystem inflammatory disorder, known as the Silk Route disease because of its geographical distribution [S9]. Uveitis occurs in over two-thirds of patients [S10] and is typically a bilateral, recurrent, non-granulomatous panuveitis with occlusive retinal vasculitis [S4]. Repeated posterior segment attacks cause irreversible retinal damage, so early and aggressive immunomodulatory treatment is the key to preserving vision [S4] [S12].

Key points - Behçet uveitis is more frequent and more severe in men in their third and fourth decades [S4]. - Untreated eye involvement can cause serious permanent damage, unlike skin, mucosal and joint disease [S3]. - Both the frequency and severity of attacks determine irreversible damage and visual prognosis [S2]. - Interferon-α, infliximab and adalimumab have shown superior efficacy compared with conventional therapy [S8]; anti-TNF agents are the core of therapy for damage-prone ocular disease [S12]. - Moderate to severe retinal involvement should be treated with biologics whenever available (expert opinion) [S2].

Evidence last checked: 2026-10-17 (PubMed abstracts).

Red flags

• Posterior segment inflammation or retinal vasculitis in a patient with oral or genital ulcers [S4] [S7].
• Young male patient, in whom the disease is more severe [S4] [S6].
• Poor prognostic signs: a high uveitis attack severity score, fluorescein leakage at the posterior pole and disruption of outer retinal layers on OCT [S8].
• Neurological, vascular or gastrointestinal symptoms alongside eye disease: these can cause serious damage and even death [S3].
• Delay in controlling inflammation is closely associated with irreversible damage [S12].

Recognise it

• Systemic picture. Recurrent oro-genital ulcers with uveitis [S7]; also articular, vascular, neurological and gastrointestinal features with a relapsing-remitting course [S9].
• Eye. Bilateral, chronic, recurrent, non-granulomatous uveitis [S10]; the eye is the most frequently involved organ [S4]. Posterior segment inflammation occurs in most patients [S8].
• Complications. Cystoid macular oedema, retinal neovascularisation, optic and retinal atrophy [S2]; macular ischaemia, vitreous haemorrhage and neovascular glaucoma [S10].
• Children. Anterior and posterior uveitis, panuveitis, retinal vasculitis and retinitis [S11].
• Genetics. HLA-B51 is among the genetic factors involved [S10].

Confirm it

• There are no laboratory biomarkers or pathognomonic histological features; diagnosis is clinical [S9].
• Classification criteria and a diagnostic algorithm have been developed for Behçet uveitis [S8].
• Fluorescein angiography and OCT are the routine imaging modalities; the clinical relevance of OCT angiography is unclear [S8].

Manage it

Before acting on this section, check the national and local guidelines, product information and regulatory approvals that apply where you practise. See the medical disclaimer.

Tier A (primary care / no specialist)

• In a patient with recurrent oral and genital ulcers, ask about red eye, floaters or blurred vision and refer for eye examination (timing in the table below) [S7].
• Behçet's syndrome is best managed by a multidisciplinary team, which gives faster diagnosis and integrated treatment [S3].

Tier B (general eye clinic)

1. Treat by location and severity of inflammation and systemic involvement [S10]; aim for rapid inflammation suppression, preserved vision and fewer recurrences [S10].
2. Corticosteroids are the mainstay, combined with other immunosuppressive agents [S3] [S10]. Conventional agents used include azathioprine, ciclosporin and cyclophosphamide [S3]. Doses are not covered by these abstracts: follow local formularies.
3. Colchicine controls mucocutaneous and joint manifestations [S12], but benefit in one organ cannot be assumed in another [S12].
4. Comanage with rheumatology for systemic disease and treatment monitoring [S3] [S6].

Tier C (specialist centre)

1. Biologics for sight-threatening disease. Anti-TNF agents have the strongest disease-specific data for ocular disease [S12]. Infliximab outcomes were better with earlier initiation, optimisation and withdrawal after remission; adalimumab first-line was superior to conventional therapy [S8].
2. Interferon-α. In a randomised trial, interferon-α was superior to ciclosporin [S8]. A 2012 review reports complete or partial remission in about 94% of patients within 2-4 weeks and suggests starting at 3-6 million IU per day (as reported in [S1]); flu-like symptoms are expected, with depression (8%) and mild leukopenia (30%) [S1].
3. Refractory disease. IL-6 and IL-1 inhibitors and other targeted therapies are used [S7] [S12]; IL-1 inhibitors were reported effective and safe for difficult ocular disease [S5].
4. Unanswered question. Head-to-head comparison of TNF inhibitors and interferon-α in uveitis is still needed [S3].

Refer when

Pitfalls

• Treating eye disease with the same stepwise approach as mucocutaneous disease; ocular disease needs early intensive therapy [S12].
• Relying on spontaneous resolution of acute signs; recurrent attacks accumulate damage [S2].
• Waiting for a laboratory test to confirm the diagnosis [S9].

Evidence notes

• Thin evidence. The search sheet for this topic contained only narrative reviews and no guideline or primary trial; trial results are reported here second-hand through reviews [S8]. EULAR Behçet recommendations appeared in another topic's sheet but not this one, so they are not cited.
• The interferon-α figures come from a 2012 review and are not trial-pooled estimates [S1].
• Not covered by these sources: anti-TNF dosing, tuberculosis screening before biologics, cost and access in Silk Road low- and middle-income countries, and cataract surgery in Behçet uveitis.

Related articles

• Vogt-Koyanagi-Harada Disease
• Biologics and Immunosuppression for Non-infectious Uveitis

References

See the numbered source list below. Each marker [S#] links to its PubMed and DOI record.